

# Long-Acting Insulin Analogues' Benefit Questioned

BY MARY ANN MOON  
Contributing Writer

The long-acting insulin analogues glargine and detemir offer only minor, if any, clinical benefit, according to Dr. K. Horvath and associates in the Cochrane Library's collaborative review group on metabolic and endocrine disorders.

Given this negligible benefit and the current lack of long-term safety and efficacy

data, "we suggest a cautious approach to treatment with [glargine or detemir]," they said in an online issue of the Cochrane Database of Systematic Reviews.

The researchers conducted a meta-analysis of eight studies that compared the new, long-acting analogues with NPH insulin, which they termed the current standard of treatment. The studies involved 2,293 patients with type 2 diabetes who were assessed for 24-52 weeks. They noted that the methodologic quality of

all of the studies was rated low, allowing for only "a cautious interpretation" of the results.

Glargine (Lantus) showed no superiority to standard insulin therapy in achieving metabolic control, and detemir (Levemir) showed only "clinically unimportant" superiority, the researchers said (Cochrane Database Syst. Rev. 2007 April 18;DOI: 10.1002/14651858.CD005613.pub3).

Nocturnal hypoglycemic events were less frequent in patients treated with either of

the two long-acting analogues than in those on standard insulin therapy, but no statistically significant advantage was noted.

None of the trials investigated possible long-term effects of treatment with the new insulin analogues, and the maximum observation period was 12 months. The meta-analysis therefore "cannot provide any further guidance on potential adverse properties, such as mitogenic effects or progression of microvascular complications." ■

**NIGHT AND DAY**

First and Only Immediate-Release oral PPI

**Zegerid**<sup>®</sup>

omeprazole/sodium bicarbonate

ZEGERID Capsules contain 300 mg of sodium per dose in the form of sodium bicarbonate (1100 mg/13 mEq). ZEGERID Powder for Oral Suspension contains 460 mg of sodium per dose in the form of sodium bicarbonate (1680 mg/20 mEq). This should be taken into consideration for patients on a sodium-restricted diet. Sodium bicarbonate is contraindicated in patients with metabolic alkalosis and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation. Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in capsules, 1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent to, and should not be substituted for, one 40 mg packet.

Please see brief summary of full Prescribing Information on the following page.

References: 1. Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. *Expert Opin Pharmacother.* 2005;6:2501-2510. 2. ZEGERID Prescribing Information. Santarus, Inc. February 2006. 3. Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. *Aliment Pharmacol Ther.* 2007;25:197-205. 4. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. *Aliment Pharmacol Ther.* 2005;21:1467-1474.

For more information, visit us at [www.zegerid.com](http://www.zegerid.com).